Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: Clinical implications and effects of B cell-targeted therapies

Clinical and Experimental Immunology

Volumn 167, Issue 1, 2012, Pages 7-14

  Vossenkamper A ^a   Lutalo, P M K ^b   Spencer, J ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

Belimumab; Rituximab; Systemic lupus erythematosus; Transitional B cells

Indexed keywords

B CELL ACTIVATING FACTOR; BELIMUMAB; EPRATUZUMAB; PLACEBO; RITUXIMAB;

CELL MATURATION; DISEASE ACTIVITY; HUMAN; HYPERGAMMAGLOBULINEMIA; INFLAMMATORY INFILTRATE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTE SUBSETS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOID TISSUE; LYMPHOPOIESIS; MICE; SJOGREN'S SYNDROME;

EID: 82655171682     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04460.x     Document Type: Review

References (90)

1. Brink R, Goodnow CC, Crosbie J etal. Immunoglobulin M and D antigen receptors are both capable of mediating B lymphocyte activation, deletion, or anergy after interaction with specific antigen. J Exp Med 1992; 176:991-1005.
2. Hartley SB, Crosbie J, Brink R, Kantor AB, Basten A, Goodnow CC. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 1991; 353:765-9.
3. Nemazee D, Buerki K. Clonal deletion of autoreactive B lymphocytes in bone marrow chimeras. Proc Natl Acad Sci USA 1989; 86:8039-43.
4. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989; 337:562-6.
5. Gay D, Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med 1993; 177:999-1008.
6. Brauninger A, Goossens T, Rajewsky K, Kuppers R. Regulation of immunoglobulin light chain gene rearrangements during early B cell development in the human. Eur J Immunol 2001; 31:3631-7.
7. Su W, Gordon JN, Barone F etal. Lambda light chain revision in the human intestinal IgA response. J Immunol 2008; 181:1264-71.
8. Harless SM, Lentz VM, Sah AP etal. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol 2001; 11:1986-9.
9. Tze LE, Schram BR, Lam KP etal. Basal immunoglobulin signaling actively maintains developmental stage in immature B cells. PLoS Biol 2005; 3:e82.
10. Cariappa A, Chase C, Liu H, Russell P, Pillai S. Naive recirculating B cells mature simultaneously in the spleen and bone marrow. Blood 2007; 109:2339-45.
11. Loder F, Mutschler B, Ray RJ etal. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med 1999; 190:75-89.
12. Allman D, Lindsley RC, DeMuth W, Rudd K, Shinton SA, Hardy RR. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol 2001; 167:6834-40.
13. Merrell KT, Benschop RJ, Gauld SB etal. Identification of anergic B cells within a wild-type repertoire. Immunity 2006; 25:953-62.
14. Srivastava B, Quinn WJ, 3rd, Hazard K, Erikson J, Allman D. Characterization of marginal zone B cell precursors. J Exp Med 2005; 202:1225-34.
15. Teague BN, Pan Y, Mudd PA etal. Cutting edge: transitional T3 B cells do not give rise to mature B cells, have undergone selection, and are reduced in murine lupus. J Immunol 2007; 178:7511-5.
16. Suryani S, Fulcher DA, Santner-Nanan B etal. Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. Blood 2010; 115:519-29.
17. Blair PA, Norena LY, Flores-Borja F etal. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010; 32:129-40.
18. Chopin M, Quemeneur L, Ripich T, Jessberger R. SWAP-70 controls formation of the splenic marginal zone through regulating T1B-cell differentiation. Eur J Immunol 2010; 40:3544-56.
19. Liu YJ, Oldfield S, MacLennan IC. Memory B cells in T cell-dependent antibody responses colonize the splenic marginal zones. Eur J Immunol 1988; 18:355-62.
20. Weill JC, Weller S, Reynaud CA. Human marginal zone B cells. Annu Rev Immunol 2009; 27:267-85.
21. Tsokos GC, Wong HK, Enyedy EJ, Nambiar MP. Immune cell signaling in lupus. Curr Opin Rheumatol 2000; 12:355-63.
22. Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 1996; 98:2549-57.
23. Bijl M, Horst G, Limburg PC, Kallenberg CG. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis 2001; 60:523-6.
24. Harada Y, Kawano MM, Huang N etal. Identification of early plasma cells in peripheral blood and their clinical significance. Br J Haematol 1996; 92:184-91.
25. Odendahl M, Jacobi A, Hansen A etal. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165:5970-9.
26. Jacobi AM, Odendahl M, Reiter K etal. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48:1332-42.
27. Cuss AK, Avery DT, Cannons JL etal. Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity. J Immunol 2006; 176:1506-16.
28. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood 2005; 105:4390-8.
29. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J Immunol 2001; 167:3610-18.
30. Yurasov S, Wardemann H, Hammersen J etal. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005; 201:703-11.
31. Yurasov S, Hammersen J, Tiller T, Tsuiji M, Wardemann H. B-cell tolerance checkpoints in healthy humans and patients with systemic lupus erythematosus. Ann NY Acad Sci 2005; 1062:165-74.
32. Fox RI. Sjogren's syndrome. Lancet 2005; 366:321-31.
33. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome. J Autoimmun 2010; 34:400-7.
34. Hansen A, Lipsky PE, Dorner T. B cells in Sjogren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther 2007; 9:218.
35. Salomonsson S, Jonsson MV, Skarstein K etal. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum 2003; 48:3187-201.
36. Le Pottier L, Devauchelle V, Fautrel A etal. Ectopic germinal centers are rare in Sjogren's syndrome salivary glands and do not exclude autoreactive B cells. J Immunol 2009; 182:3540-7.
37. Hansen A, Odendahl M, Reiter K etal. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2002; 46:2160-71.
38. Daridon C, Pers JO, Devauchelle V etal. Identification of transitional type II B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2006; 54:2280-8.
39. Chung JB, Silverman M, Monroe JG. Transitional B cells: step by step towards immune competence. Trends Immunol 2003; 24:343-9.
40. d'Arbonneau F, Pers JO, Devauchelle V, Pennec Y, Saraux A, Youinou P. BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sjogren's syndrome. Arthritis Rheum 2006; 54:115-26.
41. Traczewski P, Rudnicka L. Treatment of systemic lupus erythematosus with epratuzumab. Br J Clin Pharmacol 2010; 71:175-82.
42. Pers JO, Daridon C, Devauchelle V etal. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci 2005; 1050:34-9.
43. Cancro MP. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 2006; 65 (Suppl. 3):iii34-6.
44. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009; 119:1066-73.
45. Navarra S, Illianova E, Bae SC etal. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and steroid use in patients with seropositive SLE: BLISS-52 study. Ann Rheum Dis 2010; 69 (Suppl. 3):555.
46. van Vollenhoven RF, Zamani O, Wallace DJ etal. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study. Ann Rheum Dis 2010; 69 (Suppl. 3):74.
47. Ramanujam M, Wang X, Huang W etal. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006; 116:724-34.
48. Benson MJ, Dillon SR, Castigli E etal. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008; 180:3655-9.
49. Jacobi AM, Huang W, Wang T etal. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010; 62:201-10.
50. Furie R, Stohl W, Ginzler EM etal. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008; 10:R109.
51. Lesley R, Xu Y, Kalled SL etal. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20:441-53.
52. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Ann Rev Immunol 2003; 21:231-64.
53. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-7.
54. Looney RJ, Anolik JH, Campbell D etal. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50:2580-9.
55. Reff ME, Carner K, Chambers KS etal. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-45.
56. Bemark M, Holmqvist J, Abrahamsson J, Mellgren K. Translational Mini-Review Series: B cell subsets in disease. Reconstitution after hematopoietic stem cell transplantation - revelation of B cell developmental pathways. Clin Exp Immunol 2012; 167:15-25.
57. Anolik JH, Barnard J, Owen T etal. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007; 56:3044-56.
58. Anolik JH, Barnard J, Cappione A etal. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50:3580-90.
59. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxf) 2005; 44:1542-5.
60. Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007; 66:1259-62.
61. Reynolds JA, Toescu V, Yee CS, Prabu A, Situnayake D, Gordon C. Effects of rituximab on resistant SLE disease including lung involvement. Lupus 2009; 18:67-73.
62. Tanaka Y, Yamamoto K, Takeuchi T etal. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007; 17:191-7.
63. Albert D, Dunham J, Khan S etal. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008; 67:1724-31.
64. Jonsdottir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008; 67:330-4.
65. Tokunaga M, Saito K, Kawabata D etal. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66:470-5.
66. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009; 18:767-76.
67. Diaz-Lagares C, Garcia-Hernandez FJ, De Ramon E etal. Treatment of severe and/or refractory SLE with rituximab: analysis of 128 patients. Ann Rheum Dis 2010; 69 (Suppl. 3):550.
68. Faria RM, Isenberg DA. Three different B-cell depletion (anti-CD20 monoclonal antibodies) treatments for severe resistant systemic lupus erythematosus. Lupus 2010; 19:1256-7.
69. Jonsdottir T, Sundelin B, Zickert A, Welin Henriksson E, van Vollenhoven RF, Gunnarsson I. Lupus nephritis patients treated with rituximab: results from long term follow-up. Ann Rheum Dis 2010; 69 (Suppl. 3):553.
70. Kur-Zalewska J, Rud U, Sulek M, Tlustochowicz M, Tlustochowicz M. Rituximab in patients with SLE and inadequate response to traditional immunosuppressive therapy. Ann Rheum Dis 2010; 69 (Suppl. 3):685.
71. Marenco J, Fernandez-Nebro A, Lopez-Longo FJ etal. Effectiveness and safety of rituximab in patients with SLE refractory to standard therapy. Ann Rheum Dis 2010; 69 (Suppl. 3):554.
72. Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006; 65:942-5.
73. Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E etal. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010; 28:468-76.
74. Terrier B, Amoura Z, Ravaud P etal. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62:2458-66.
75. Torgashina A, Soloviev SK, Alexandrova EN, Radenska SG, Nasonov EL. Efficacy of rituximab in lupus nephritis: data from Russian Register. Ann Rheum Dis 2010; 69 (Suppl. 3):686.
76. Vital EM, Dass S, Buch MH etal. Treatment of SLE with B cell depletion: predicting response and managing loss of response. Ann Rheum Dis 2010; 69 (Suppl. 3):558.
77. Merrill JT, Neuwelt CM, Wallace DJ etal. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62:222-33.
78. Furie RA, Looney JR, Rovin B etal. Efficacy and safety of rituximab in patients with proliferative lupus nephritis: results from the randomized, double-blind phase III LUNAR study. Ann Rheum Dis 2010; 69 (Suppl. 3):549.
79. Furie R, Rovin B, Appel G etal. Effect of rituximab on anti-double stranded DNA antibody and C3 levels and relationship to response: results from the LUNAR trial. Ann Rheum Dis 2010; 69 (Suppl. 3):550.
80. Tew GW, Rabbee N, Wolslegel K etal. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus 2010; 19:146-57.
81. Dass S, Bowman SJ, Vital EM etal. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67:1541-4.
82. Looney RJ. Will targeting B cells be the answer for Sjogren's syndrome? Arthritis Rheum 2007; 56:1371-7.
83. Meijer JM, Pijpe J, Vissink A, Kallenberg CG, Bootsma H. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009; 68:284-5.
84. Jacobi AM, Goldenberg DM, Hiepe F, Radbruch A, Burmester GR, Dorner T. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008; 67:450-7.
85. Kawasaki N, Rademacher C, Paulson JC. CD22 regulates adaptive and innate immune responses of B cells. J Innate Immun 2011; 3:411-19.
86. Sato S, Jansen PJ, Tedder TF. CD19 and CD22 expression reciprocally regulates tyrosine phosphorylation of Vav protein during B lymphocyte signaling. Proc Natl Acad Sci USA 1997; 94:13158-62.
87. Daridon C, Blassfeld D, Reiter K etal. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther 2010; 12:R204.
88. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8:R74.
89. Steinfeld SD, Tant L, Burmester GR etal. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006; 8:R129.
90. Kalunian K, Wallace DJ, Petri M etal. BILAG-measured improvement in moderately and severely affected body systems in patients with SLE by epratuzumab: results from EMBLEM, a phase IIB study. Annals Rheum Dis 2010; 69 (Suppl. 3):553.